Gilead Sciences Inc is > 10% Shareholder of Allovir, Inc.. Currently has a direct ownership of 16.6 Million shares of ALVR, which is worth approximately $14.8 Million. The most recent transaction as insider was on Jun 27, 2023, when has been sold 2,930,870 shares (Common Stock) at a price of $3.75 per share, resulting in proceeds of $10,990,762. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 16.6M
0% 3M change
0% 12M change
Total Value Held $14.8 Million

GILEAD SCIENCES INC Transaction History

Date Transaction Value Shares Traded Shares Held Form
Jun 27 2023
BUY
Open market or private purchase
$10,990,762 $3.75 p/Share
2,930,870 Added 14.98%
16,635,286 Common Stock

Also insider at

RCUS
Arcus Biosciences, Inc. Healthcare
KYTX
Kyverna Therapeutics, Inc.
XLO
Xilio Therapeutics, Inc. Healthcare
ASMB
ASSEMBLY BIOSCIENCES, INC. Healthcare
GSI

Gilead Sciences Inc

> 10% Shareholder
Foster City, CA

Track Institutional and Insider Activities on ALVR

Follow Allovir, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ALVR shares.

Notify only if

Insider Trading

Get notified when an Allovir, Inc. insider buys or sells ALVR shares.

Notify only if

News

Receive news related to Allovir, Inc.

Track Activities on ALVR